Table 1.
Baseline characteristics
| Placebo, n=88 | Irbesartan, n=104 | ||
|---|---|---|---|
| Age (years) | |||
| 6 to <11 | 19 (22%) | 21 (20%) | |
| 11 to <18 | 26 (30%) | 27 (26%) | |
| 18 to <25 | 13 (15%) | 22 (21%) | |
| 25 to <41 | 30 (34%) | 34 (33%) | |
| Sex | |||
| Female | 42 (48%) | 57 (55%) | |
| Male | 46 (52%) | 47 (45%) | |
| Ethnicity | |||
| White British, Irish, or other | 78 (89%) | 97 (93%) | |
| Asian | 6 (7%) | 2 (2%) | |
| Black African or Caribbean | 2 (2%) | 1 (1%) | |
| Mixed | 1 (1%) | 2 (2%) | |
| Other | 1 (1%) | 2 (2%) | |
| Aortic root diameter, mm | 34·4 (5·8) | 34·4 (5·5) | |
| Aortic Z score | 3·3 (2·1) | 3·2 (2·0) | |
| β-blocker use | 52 (59%) | 56 (54%) | |
| Systolic blood pressure, mm Hg | 109 (15)* | 110 (16) | |
| Diastolic blood pressure, mm Hg | 64 (11)* | 66 (12) | |
| Heart rate | 72 (13)* | 72 (14) | |
| Height, cm | 178 (161–186) | 175 (163–187) | |
| Weight, kg | 60·7 (44·6–73·1) | 61·6 (44·0–76·8) | |
| Body-mass index, kg/m2 | 18·9 (16·0–22·4) | 19·3 (15·8–22·5) | |
| Body surface area, m2 | 1·78 (1·50–1·96) | 1·78 (1·44–2·01) | |
| Lower segment, cm | 94 (84–100)* | 94 (86–100) | |
| Arm span, cm | 181 (164–190)† | 179 (163–192) | |
| Creatinine, μmol/L | 56 (14)* | 56 (16)* | |
Data are n (%), mean (SD), or median (IQR).
*
One patient with missing data.
†
Two patients with missing data.